Paul Gleeson, Matthew

Loading...
Thumbnail Image
Preferred name
Paul Gleeson, Matthew
Alternative Name
Paul Gleeson, M.
Main Affiliation
Email
paul.gl@kmitl.ac.th

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Assessment of the Utility of Chitosan in Drug Delivery of Sulfamethoxazole
    (2024-01-01)
    Soontorntepwarakul, Nussara
    ;
    Boonyarattanakalin, Kanokthip
    ;
    Srirussamee, Kasama
    ;
    Paul Gleeson, M.
    The objective of this research was to develop chitosan (CS) nanoparticles (NP) and microfibres (MF) for oral delivery applications related to low solubility drugs. The ionic gelation method in conjunction with freeze-drying was used to produce crosslinked chitosan material. Dynamic light scattering (DLS) was used to characterize particle size and polydispersity index (PDI). Surface morphology was analyzed using scanning electron microscopy (SEM). The antibiotic drug sulfamethoxazole (SMO) was loaded onto the chitosan nano/micro material. The degree of loading, loading efficiency and the release kinetics were investigated using high-performance liquid chromatography (HPLC) and UV-visible spectrophotometry, respectively. We found that CS nanoparticles have the potential to improve the delivery properties of SMO due to their more rapid release compared to microfibres or traditional tablet formulations.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Design, Computational Evaluation and Route of Synthesis Validation of New JAK2 inhibitors to Treat Inflammatory Diseases
    (2025-01-01)
    Pornsupawat, Jarukorn
    ;
    Paul Gleeson, M.
    In this research we report the design of new JAK2 inhibitors using structure-based and ligand-based design approaches. Novel JAK2 inhibitors were designed containing biostatic modifications developed from related scaffolds. The JAK2 binding characteristics were studied using molecular docking and an assessment of their overall drug likeness was made though the prediction of key physical properties. Validation of routes of synthesis have been undertaken to assess the feasibility of preparing the compounds. Our results suggest that the new molecules have desirable physical properties and are highly likely to be inhibitors of JAK2 kinase. In addition, we have validated the synthetic conditions and intermediates needed for their preparation by preparing 4 key exemplars.